OBJECTIVES: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer. METHODS: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed. RESULTS: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/cytopoenia (n = 19, 82.6%) and gastrointestinal effects (n = 19, 82.6%). Surgical resection was successful in seven (30.4%) patients. Margins were negative in six (85.7%) of these seven patients. Positive lymph nodes were identified in three (42.9%) of seven patients. Overall survival was 11.5 months. Surgery provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival in resected patients was 17.2 months. CONCLUSIONS: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.
OBJECTIVES: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer. METHODS: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed. RESULTS: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/cytopoenia (n = 19, 82.6%) and gastrointestinal effects (n = 19, 82.6%). Surgical resection was successful in seven (30.4%) patients. Margins were negative in six (85.7%) of these seven patients. Positive lymph nodes were identified in three (42.9%) of seven patients. Overall survival was 11.5 months. Surgery provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival in resected patients was 17.2 months. CONCLUSIONS: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.
Authors: A G Morganti; L Trodella; V Valentini; G B Doglietto; P Ziccarelli; G Macchia; S Alfieri; D Smaniotto; S Luzi; M G Brizi; G Fadda; M Fiorino; C Di Gesú; N Cellini Journal: Tumori Date: 1999 Jan-Feb Impact factor: 2.098
Authors: E Bajetta; M Di Bartolomeo; S C Stani; S Artale; S B Ricci; F Bozzetti; V Mazzaferro; L Toffolatti; R Buzzoni Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: Sana Al-Sukhun; Mark M Zalupski; Edgar Ben-Josef; Vainutis K Vaitkevicius; Philip A Philip; Renate Soulen; Donald Weaver; Volkan Adsay; Lance K Heilbrun; Kenneth Levin; Jeffery D Forman; Anthony F Shields Journal: Am J Clin Oncol Date: 2003-12 Impact factor: 2.339
Authors: David C Linehan; Marcus C B Tan; Steven M Strasberg; Jeffrey A Drebin; William G Hawkins; Joel Picus; Robert J Myerson; Robert S Malyapa; Michael Hull; Kathryn Trinkaus; Benjamin R Tan Journal: Ann Surg Date: 2008-08 Impact factor: 12.969
Authors: Valerie Magnin; Vincent Moutardier; Marie Helene Giovannini; Bernard Lelong; Marc Giovannini; Frederic Viret; Genevieve Monges; Valerie Jeanne Bardou; Claude Alzieu; Jean Robert Delpero Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: Alice C Wei; Fang-Shu Ou; Qian Shi; Xiomara Carrero; Eileen M O'Reilly; Jeffrey Meyerhardt; Robert A Wolff; Hedy L Kindler; Douglas B Evans; Vikram Deshpande; Joseph Misdraji; Eric Tamm; Dushyant Sahani; Malcolm Moore; Elliot Newman; Nipun Merchant; Jordan Berlin; Laura W Goff; Peter Pisters; Mitchell C Posner Journal: Ann Surg Oncol Date: 2019-08-15 Impact factor: 5.344
Authors: Mashaal Dhir; Gautam K Malhotra; Davendra P S Sohal; Nicholas A Hein; Lynette M Smith; Eileen M O'Reilly; Nathan Bahary; Chandrakanth Are Journal: World J Surg Oncol Date: 2017-10-10 Impact factor: 2.754